Stauffer Christopher S, Brown Melanie R, Adams Dee, Cassity Marca, Sevelius Jae
Social Neuroscience and Psychotherapy Lab, Oregon Health and Science Institute, Department of Psychiatry, Portland, OR, United States.
Portland VA Health Care System, Department of Mental Health, Portland, OR, United States.
Front Psychiatry. 2022 Oct 10;13:932605. doi: 10.3389/fpsyt.2022.932605. eCollection 2022.
Transgender and gender diverse (TGD) people experience stigma, discrimination, trauma, and post-traumatic stress disorder (PTSD) at higher rates compared to the general population; however, TGD people have been underrepresented in PTSD research. Clinical trials of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy demonstrate promising safety and efficacy for the treatment of PTSD. Issues related to equitable access, power imbalances in the therapeutic relationship, and vulnerable states of consciousness occasioned by MDMA are magnified when working with people affected by structural vulnerabilities and health disparities, and community engagement in research planning and implementation is essential. To inform the inclusion and safety of TGD people in future MDMA-assisted psychotherapy research, the aims of the current study were to: characterize TGD experiences with trauma-related mental health care, assess openness of TGD people to participate in experimental PTSD research, and to gather specific feedback on protocol design for conducting MDMA-assisted psychotherapy with TGD people.
We conducted three virtual focus group discussions (FGDs) with 5-6 participants each ( = 17). Eligible TGD participants had a history of receiving trauma-related mental health care. Each FGD was facilitated by two licensed clinicians who identified as TGD. Qualitative data analysis was conducted via an iterative process of identification of recurrent patterns and themes.
We have identified several key issues TGD people face when seeking and engaging in trauma-related mental health care, including barriers to receiving adequate gender-affirming and trauma-informed mental health care and frustration with providers lacking cultural humility. Suggested amendments to MDMA-assisted psychotherapy protocols include: routine collection of trans-inclusive gender identity data, implementing an explicit gender-affirming treatment approach, ensuring a culturally safe setting, and diversifying co-therapy dyads.
The inclusion of TGD voices in early conversations about emerging experimental PTSD interventions promotes equitable access, in the context of health and healthcare disparities, and helps researchers understand the needs of the community and tailor research to meet those needs. Through an ongoing conversation with the TGD community, we aim to incorporate a gender-affirming approach into existing research protocols and inform future applications of MDMA-assisted psychotherapy in addressing the effects of minority stress and boosting resilience.
与普通人群相比,跨性别者和性别多样化者(TGD)遭受耻辱、歧视、创伤和创伤后应激障碍(PTSD)的比例更高;然而,TGD人群在PTSD研究中的代表性一直不足。3,4-亚甲基二氧甲基苯丙胺(MDMA)辅助心理治疗的临床试验显示出治疗PTSD有良好的安全性和有效性。在与受结构性脆弱性和健康差距影响的人群合作时,与公平获取、治疗关系中的权力不平衡以及MDMA引起的意识脆弱状态相关的问题会被放大,社区参与研究规划和实施至关重要。为了使TGD人群能够纳入未来MDMA辅助心理治疗研究并确保其安全性,本研究的目的是:描述TGD人群在创伤相关心理健康护理方面的经历,评估TGD人群参与实验性PTSD研究的意愿,并收集关于对TGD人群进行MDMA辅助心理治疗方案设计的具体反馈。
我们进行了三次虚拟焦点小组讨论(FGD),每次有5 - 6名参与者(共17人)。符合条件的TGD参与者有接受过创伤相关心理健康护理的历史。每次FGD由两名自称TGD的持牌临床医生主持。通过反复识别反复出现的模式和主题的过程进行定性数据分析。
我们确定了TGD人群在寻求和接受创伤相关心理健康护理时面临的几个关键问题,包括获得充分的性别肯定和创伤知情心理健康护理的障碍,以及对缺乏文化谦逊的提供者感到沮丧。对MDMA辅助心理治疗方案的建议修订包括:常规收集跨性别包容性别的身份数据,实施明确的性别肯定治疗方法,确保文化安全的环境,以及使联合治疗二元组多样化。
在关于新兴的实验性PTSD干预措施的早期讨论中纳入TGD人群的声音,在健康和医疗差距的背景下促进了公平获取,并帮助研究人员了解社区的需求并调整研究以满足这些需求。通过与TGD社区的持续对话,我们旨在将性别肯定方法纳入现有研究方案,并为MDMA辅助心理治疗在解决少数群体压力影响和增强复原力方面的未来应用提供信息。